Lung Adenocarcinoma Gene-Edited Cell Lines for Drug Discovery

Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC), accounting for approximately 40% of all lung cancer cases. According to the World Health Organization (WHO), lung cancer remains the leading cause of cancer-related death worldwide, with an estimated 1.8 million deaths annually (WHO, 2022). The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports a 5-year relative survival rate of only 24% for all stages combined, dropping to 7% for distant-stage disease. Major risk factors include tobacco smoking, exposure to radon, air pollution, and occupational carcinogens. Despite advances in targeted therapies and immunotherapies, intrinsic and acquired resistance remain significant clinical challenges, driving the need for robust preclinical models.

LUAD is an ideal model for mechanistic studies due to its well-characterized molecular subtypes, extensive public genomic datasets (e.g., TCGA, COSMIC), and the presence of actionable driver mutations. Key open questions include the mechanisms of resistance to KRAS G12C inhibitors, the role of co-occurring mutations (e.g., STK11, KEAP1), and the tumor microenvironment's influence on therapy response. Gene-edited cell models provide a controlled system to dissect these questions.

LUAD pathogenesis involves the dysregulation of several key signaling pathways:

• • MAPK/ERK pathway: Activation via KRAS mutations (G12C, G12D, G12V) leads to uncontrolled cell proliferation.
• • PI3K/AKT/mTOR pathway: Mutations in PIK3CA or loss of PTEN promote survival and growth.
• • p53 pathway: Inactivating mutations in TP53 impair apoptosis and cell cycle arrest.
• • Cell cycle regulation: CDKN2A loss or CCND1 amplification drives G1/S transition.
• • Ordered steps in KRAS-driven LUAD:

1. KRAS mutation (e.g., G12C) leads to constitutive GTP binding.

2. Activation of RAF-MEK-ERK cascade.

3. Increased transcription of pro-proliferative genes (MYC, Cyclin D1).

4. Cooperation with loss of tumor suppressors (TP53, STK11) for full transformation.

Data from TCGA (Cancer Genome Atlas Research Network, Nature 2014) and COSMIC (Catalogue of Somatic Mutations in Cancer):

• • Key deregulated networks in LUAD:
• • Wnt/beta-catenin: CTNNB1 mutations or APC loss lead to nuclear beta-catenin accumulation and transcription of MYC, CCND1.
• • MAPK/ERK: KRAS, BRAF, and NF1 mutations drive sustained signaling.
• • PI3K/AKT: PIK3CA mutations, PTEN loss, and AKT amplification promote survival.
• • NRF2/KEAP1: KEAP1 mutations stabilize NRF2, leading to antioxidant response and chemoresistance.
• • Hippo/YAP: LATS1/2 inactivation or YAP amplification drives proliferation and metastasis.

Commonly used LUAD cell lines and their key mutations:

Organoid models derived from patient tumors retain heterogeneity and 3D architecture, enabling more physiologically relevant drug testing and CRISPR screens.

• • Preclinical animal models for LUAD:
• • Patient-derived xenografts (PDX): Implantation of human tumor fragments into immunodeficient mice; preserve tumor heterogeneity and stromal interactions.
• • Genetically engineered mouse models (GEMM): Conditional Kras G12D; Trp53 deletion (KP model) recapitulates human LUAD progression.
• • Induced models: Urethane or tobacco carcinogen (NNK) exposure in mice induces lung tumors with Kras mutations.
• • Syngeneic models: Murine LUAD cell lines (e.g., LLC) implanted into immunocompetent mice for immunotherapy studies.

• • CRISPR/Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, eliminating confounding background mutations. Examples include:
• • TP53 knockout in A549 cells to study p53 loss-of-function.
• • KRAS G12D knock-in in wild-type lung epithelial cells to model oncogenic activation.
• • EGFR T790M knock-in in PC9 cells to study resistance to first-generation EGFR inhibitors.

Commercially available, sequence-verified gene-edited cell models (e.g., knockout, knock-in, reporter lines) accelerate research by providing ready-to-use, validated tools. These models are available from multiple commercial sources and can be customized for specific mutations or reporter constructs.

• • Gene-edited cell lines are essential for functional validation of candidate genes identified from genomic studies. For example:
• • Knockout of STK11 in A549 cells confirmed its role in metabolic reprogramming and sensitivity to mTOR inhibitors.
• • Knock-in of KRAS G12C in H1299 cells enabled study of mutant-specific signaling and inhibitor sensitivity.
• • TP53 knockout in H1975 cells demonstrated p53-dependent regulation of apoptosis in response to DNA damage.

• • Isogenic cell pairs (e.g., wild-type vs. KRAS G12C knock-in) allow high-throughput screening for mutant-selective inhibitors. Resistance mechanisms can be modeled by:
• • Chronic exposure of isogenic lines to targeted drugs (e.g., osimertinib) followed by whole-exome sequencing to identify acquired mutations.
• • CRISPR knockout screens in resistant lines to identify genes whose loss restores sensitivity.

• • CRISPR-based synthetic lethality screens in LUAD cell lines identify vulnerabilities specific to genetic backgrounds. For example:
• • KEAP1 knockout cells are hypersensitive to glutaminase inhibitors, suggesting a biomarker for patient stratification.
• • STK11 loss sensitizes cells to phenformin, a mitochondrial complex I inhibitor.
• • Genome-wide CRISPR screens in KRAS mutant lines have identified novel dependencies such as TBK1 and GATA2.